Literature DB >> 6527137

Dopaminergic properties of mesulergine (CU 32-085) and its metabolites.

A Enz, P Donatsch, R Nordmann.   

Abstract

Mesulergine, an 8-alpha-aminoergoline, is now proven to be of utility in the clinic as an antiparkinsonian drug. However, the molecule itself shows in vitro and in vivo antidopaminergic properties. Mesulergine is rapidly metabolized into several pharmacologically active DA agonists. The influence of mesulergine on central DA metabolism in rats is dependent on the route of drug administration. It was possible to determine the different metabolites of this drug in plasma as well as in rat striatum. A correlation between the actual present concentration of the parent drug and DAergic metabolites and the net action on striatal DA metabolism was found. It may be concluded that mesulergine itself lacks DAergic activity but occupies DA receptors and is very rapidly metabolized into potent DA agonists.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6527137     DOI: 10.1007/bf01249095

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  13 in total

1.  Biphasic influence of a 8 alpha-amino ergoline, CU 32-085, on striatal dopamine synthesis and turnover in vivo in the rat.

Authors:  A Enz
Journal:  Life Sci       Date:  1981-11-23       Impact factor: 5.037

2.  Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.

Authors:  E Schneider; K Hubener; P A Fischer
Journal:  Neurology       Date:  1983-04       Impact factor: 9.910

3.  [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].

Authors:  E Ringwald; D Hirt; R Markstein; J M Vigouret
Journal:  Nervenarzt       Date:  1982-02       Impact factor: 1.214

4.  Inhibition by dopamine agonists of dopamine accumulation following gamma-hydroxybutyrate treatment.

Authors:  A Handforth; T L Sourkes
Journal:  Eur J Pharmacol       Date:  1975-12       Impact factor: 4.432

5.  Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism.

Authors:  W Kehr
Journal:  Eur J Pharmacol       Date:  1984-01-13       Impact factor: 4.432

6.  Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride.

Authors:  H Wachtel; W Kehr; G Sauer
Journal:  Life Sci       Date:  1983-12-26       Impact factor: 5.037

7.  Two novel prolactin release-inhibiting 8 alpha-amino-ergolines.

Authors:  E Flückiger; U Briner; H R Bürki; P Marbach; H R Wagner; W Doepfner
Journal:  Experientia       Date:  1979-12-15

8.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

9.  Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain.

Authors:  J Glowinski; L L Iversen
Journal:  J Neurochem       Date:  1966-08       Impact factor: 5.372

10.  Long-term treatment of parkinsonism with bromocriptine.

Authors:  D B Calne; C Plotkin; A C Williams; J G Nutt; A Neophytides; P F Teychenne
Journal:  Lancet       Date:  1978-04-08       Impact factor: 79.321

View more
  5 in total

Review 1.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.

Authors:  H Baas; E Schneider; P A Fischer; G Japp
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

3.  Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.

Authors:  E Schneider; H Baas; P A Fischer; G Japp
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

4.  Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Khoa Hoang; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2015-10-12       Impact factor: 3.345

5.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.